Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) has released a new investor presentation providing a business update on the company and its portfolio of predictive genomics products for human and animal health, including its patented geneType multi-risk test.
The non-invasive geneType multi-risk test is designed to uncover hidden risks of common yet serious diseases, identifying individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes.
Testing of a statistically significant number of people in Australia and the US since the geneType risk assessment tests became available has revealed that 79.5% of people tested showed an elevated risk for at least one disease. By providing insights into their health they have never had before, people are empowered to act.
The company’s current focus is on driving sales and scaling geneType.
Another recent highlight was the company’s launch in May of a novel comprehensive risk assessment test that covers 100% of women at risk of developing breast and ovarian cancer.
The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary disease, including those with common gene mutations and sporadic disease.
Launched at the inaugural “Know Your Risk” event in California, USA, the event provided invaluable insights of the role of genomics in women’s health.
A multi-brand global strategy
GTG has a global operation, a comprehensive human and animal health portfolio, and is exploring new market opportunities in Canada, New Zealand, Europe, and Southeast Asia.
GTG is executing a multi-brand strategy and has multiple pathways to markets. These include medical and payer business to business (B2B), consumer initiated testing (CIT) with medical supervision, and direct to consumer testing (FTC) with no medical supervision.
In addition to its geneType multi risk test, GTG has two other business units in its portfolio - easyDNA and AffinityDNA, which are both currently profitable and boast gross margins in excess of 55%. geneType is on track to be profitable in 12 months as it sees growth in B2B and CIT sales.
The company’s portfolio includes:
- comprehensive breast and ovarian cancer;
- patented geneType multi-risk test;
- non-invasive prenatal testing (NIPT);
- carrier screen testing;
- pharmacogenomics;
- oncogenetic and monogenic diseases; and
- animal care.
Read more on Proactive Investors AU
